RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCOPUS SCIE

      Effects of percutaneous angioplasty on kidney function and blood pressure in patients with atherosclerotic renal artery stenosis

      한글로보기

      https://www.riss.kr/link?id=A106374155

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Background: Previous randomized controlled trials of revascularization for atherosclerotic renal artery stenosis (ARAS) were not successful. We investigated the effects of percutaneous transluminal angioplasty with stent insertion (PTA/S) on kidney function and blood pressure (BP) control in patients with ARAS.
      Methods: From 2000 to 2017, 47 subjects who underwent PTA/S for ARAS were identified. A high-risk group was defined, composed of patients having one or more of the following clinical presentations: pulmonary edema, refractory hypertension, and rapid deterioration of kidney function. Subjects who met the criteria of ‘kidney function improvement’ or ‘hypertension improvement’ after PTA/S were classified as responders.
      Results: Twenty-one (44.7%) subjects were classified into the high-risk group. Two subjects (8.0%) in the low-risk group (n = 25) and 5 subjects (27.8%) in the high-risk group (n = 18) showed improvement in kidney function after PTA/S (P = 0.110). In patients with rapid decline of kidney function, estimated glomerular filtration rate improved from 28 (interquartile range [IQR], 10-45) mL/min/1.73 m2 to 41 (IQR, 16-67) mL/min/1.73 m2 at 4 months after PTA/S, although the difference was not significant (P = 0.084). Regarding BP control, 9 (36.0%) and 14 (77.8%) subjects showed improvement after PTA/S in the low- (n = 25) and high-risk (n = 18) groups, respectively (P = 0.007).
      In patients with refractory hypertension, the systolic BP dropped from 157 (IQR, 150-164) mmHg to 140 (IQR, 131- 148) mmHg at 4 months after PTA/S (P = 0.005). Twenty-five subjects were defined as responders and comprised a significant proportion of the high-risk group (P = 0.004).
      Conclusion: PTA/S might improve BP control and kidney function in patients with ARAS presenting with highrisk clinical features. The optimal application of PTA/S should be based on individual assessment of the clinical significance of renal artery stenosis.
      번역하기

      Background: Previous randomized controlled trials of revascularization for atherosclerotic renal artery stenosis (ARAS) were not successful. We investigated the effects of percutaneous transluminal angioplasty with stent insertion (PTA/S) on kidney fu...

      Background: Previous randomized controlled trials of revascularization for atherosclerotic renal artery stenosis (ARAS) were not successful. We investigated the effects of percutaneous transluminal angioplasty with stent insertion (PTA/S) on kidney function and blood pressure (BP) control in patients with ARAS.
      Methods: From 2000 to 2017, 47 subjects who underwent PTA/S for ARAS were identified. A high-risk group was defined, composed of patients having one or more of the following clinical presentations: pulmonary edema, refractory hypertension, and rapid deterioration of kidney function. Subjects who met the criteria of ‘kidney function improvement’ or ‘hypertension improvement’ after PTA/S were classified as responders.
      Results: Twenty-one (44.7%) subjects were classified into the high-risk group. Two subjects (8.0%) in the low-risk group (n = 25) and 5 subjects (27.8%) in the high-risk group (n = 18) showed improvement in kidney function after PTA/S (P = 0.110). In patients with rapid decline of kidney function, estimated glomerular filtration rate improved from 28 (interquartile range [IQR], 10-45) mL/min/1.73 m2 to 41 (IQR, 16-67) mL/min/1.73 m2 at 4 months after PTA/S, although the difference was not significant (P = 0.084). Regarding BP control, 9 (36.0%) and 14 (77.8%) subjects showed improvement after PTA/S in the low- (n = 25) and high-risk (n = 18) groups, respectively (P = 0.007).
      In patients with refractory hypertension, the systolic BP dropped from 157 (IQR, 150-164) mmHg to 140 (IQR, 131- 148) mmHg at 4 months after PTA/S (P = 0.005). Twenty-five subjects were defined as responders and comprised a significant proportion of the high-risk group (P = 0.004).
      Conclusion: PTA/S might improve BP control and kidney function in patients with ARAS presenting with highrisk clinical features. The optimal application of PTA/S should be based on individual assessment of the clinical significance of renal artery stenosis.

      더보기

      참고문헌 (Reference)

      1 UK Medicines Information, "What are appropriate doses to use when switching hypertensive patients to amlodipine from lercanidipine or lacidipine?" Surrey and Sussex Healthcare NHS Trust

      2 Levy PD, "Total antihypertensive therapeutic intensity score and its relationship to blood pressure reduction" 10 : 906-916, 2016

      3 Mohan IV, "The management of renal artery stenosis : an alternative interpretation of ASTRAL and CORAL" 49 : 465-473, 2015

      4 Vassallo D, "The effect of revascularization in patients with anatomically significant atherosclerotic renovascular disease presenting with high-risk clinical features" 33 : 497-506, 2018

      5 Cooper CJ, "Stenting and medical therapy for atherosclerotic renal-artery stenosis" 370 : 13-22, 2014

      6 ASTRAL Investigators, "Revascularization versus medical therapy for renal-artery stenosis" 361 : 1953-1962, 2009

      7 Ram CV, "Renovascular hypertension" 6 : 575-579, 1997

      8 Ma Z, "Renal artery stent in solitary functioning kidneys: 77% of benefit: a systematic review with meta-analysis" 95 : e4780-, 2016

      9 Derkx FH, "Renal artery stenosis and hypertension" 344 : 237-239, 1994

      10 Hemmelgarn BR, "Relation between kidney function, proteinuria, and adverse outcomes" 303 : 423-429, 2010

      1 UK Medicines Information, "What are appropriate doses to use when switching hypertensive patients to amlodipine from lercanidipine or lacidipine?" Surrey and Sussex Healthcare NHS Trust

      2 Levy PD, "Total antihypertensive therapeutic intensity score and its relationship to blood pressure reduction" 10 : 906-916, 2016

      3 Mohan IV, "The management of renal artery stenosis : an alternative interpretation of ASTRAL and CORAL" 49 : 465-473, 2015

      4 Vassallo D, "The effect of revascularization in patients with anatomically significant atherosclerotic renovascular disease presenting with high-risk clinical features" 33 : 497-506, 2018

      5 Cooper CJ, "Stenting and medical therapy for atherosclerotic renal-artery stenosis" 370 : 13-22, 2014

      6 ASTRAL Investigators, "Revascularization versus medical therapy for renal-artery stenosis" 361 : 1953-1962, 2009

      7 Ram CV, "Renovascular hypertension" 6 : 575-579, 1997

      8 Ma Z, "Renal artery stent in solitary functioning kidneys: 77% of benefit: a systematic review with meta-analysis" 95 : e4780-, 2016

      9 Derkx FH, "Renal artery stenosis and hypertension" 344 : 237-239, 1994

      10 Hemmelgarn BR, "Relation between kidney function, proteinuria, and adverse outcomes" 303 : 423-429, 2010

      11 Kądziela J, "Prognostic value of renal fractional flow reserve in blood pressure response after renal artery stenting(PREFER study)" 20 : 418-422, 2013

      12 Leesar MA, "Prediction of hypertension improvement after stenting of renal artery stenosis : comparative accuracy of translesional pressure gradients, intravascular ultrasound, and angiography" 53 : 2363-2371, 2009

      13 Mitchell JA, "Predicting blood pressure improvement in hypertensive patients after renal artery stent placement : renal fractional flow reserve" 69 : 685-689, 2007

      14 Ritchie J, "High-risk clinical presentations in atherosclerotic renovascular disease : prognosis and response to renal artery revascularization" 63 : 186-197, 2014

      15 Inker LA, "Estimating glomerular filtration rate from serum creatinine and cystatin C" 367 : 20-29, 2012

      16 Evridiki Karanikola, "Endovascular Management of Atherosclerotic Renal Artery Stenosis: Post-Cardiovascular Outcomes in Renal Atherosclerotic Lesions Era Winner or False Alarm?" 대한혈관외과학회 33 (33): 1-15, 2017

      17 "Drug comparisons - beta blockers equivalent doses" GlobalRPh Inc

      18 "Dihydropyridine calcium channel blocker interchange" Vancouver Acute

      19 Manolis AS, "Current status of renal artery angioplasty and stenting for resistant hypertension : a case series and review of the literature" 13 : 93-103, 2017

      20 Harada K, "Comparison of the antagonistic activity of tamsulosin and doxazosin at vascular alpha 1-adrenoceptors in humans" 354 : 557-561, 1996

      21 "Comparison of angiotensin converting enzyme (ACE) inhibitors" Vancouver Acute

      22 Kumbhani DJ, "Clinical outcomes after percutaneous revascularization versus medical management in patients with significant renal artery stenosis : a meta-analysis of randomized controlled trials" 161 : 622.e1-630.e1, 2011

      23 Fujihara M, "Clinical outcome of renal artery stenting for hypertension and chronic kidney disease up to 12 months in the J-RAS Study-prospective, single-arm, multicenter clinical study" 79 : 351-359, 2015

      24 Jenks S, "Balloon angioplasty, with and without stenting, versus medical therapy for hypertensive patients with renal artery stenosis" (12) : CD002944-, 2014

      25 Rossetti G, "Antihypertensive effect of barnidipine 10 mg or amlodipine 5 to 10 mg once daily in treatment-naive patients with essential hypertension : A 24-week, randomized, open-label, pilot study" 69 : 192-206, 2008

      26 "Angiotensin II receptor blockers" GlobalRPh Inc

      27 Gerstein HC, "Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals" 286 : 421-426, 2001

      28 Hirsch AT, "ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease)--summary of recommendations" 17 : 1383-1397, 2006

      29 Mancia G, "2013 ESH/ESC guidelines for the management of arterial hypertension : the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension(ESH)and of the European Society of Cardiology(ESC)" 34 : 2159-2219, 2013

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2020-01-01 평가 등재학술지 유지 (해외등재 학술지 평가) KCI등재
      2011-11-29 학술지명변경 한글명 : The Korean Journal of Nephrology -> Kidney Research and Clinical Practice
      외국어명 : 미등록 -> Kidney Research and Clinical Practice
      KCI등재
      2010-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2008-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2007-02-22 학술지명변경 한글명 : 대한신장학회지 -> The Korean Society of Nephrology KCI등재
      2007-02-22 학술지명변경 한글명 : 대한신장학회지 -> The Korean Journal of Nephrology KCI등재
      2005-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2004-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2002-01-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 0.21 0.21 0.17
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0.14 0.1 0.422 0.11
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼